サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439686

臨床診断 - 世界市場の考察、競合情勢、市場予測（2030年）

Clinical Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
臨床診断 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の臨床診断の市場規模は、2023年に701億1,000万米ドルに達し、2024年～2030年の予測期間にCAGRで7.02％の成長が見込まれます。臨床診断に対する需要の高まりは、主に肝疾患、血液疾患、がんなどのさまざまな慢性疾患の負担の増加に起因しています。さらに、ポイントオブケア臨床診断検査の採用の増加、世界中での臨床診断ラボ新設に向けた戦略的事業活動の高まり、製品ポートフォリオにおける技術の進歩などが、2024年～2030年の予測期間に世界の臨床診断市場を強化する見込みです。

臨床診断の市場力学

臨床診断市場は、心血管疾患、糖尿病、がんなどのさまざまな慢性疾患の急増により、現在勢いを増しています。

2023年に発表された国際糖尿病連合（International Diabetes Federation）の統計によると、同年に5億3,700万人の成人（20～79歳）が糖尿病を患っていると推定されています。さらに同統計では、糖尿病患者は2030年までに6億4,300万人、2045年までに7億8,300万人に増加すると予測しています。

臨床診断検査は、あらゆる疾患の早期診断に決定的な影響を与え、さらに適切な管理に役立ちます。例えば、A1C検査は過去2、3ヶ月の平均血糖値を測定します。検査値が5.7％未満は正常、5.7～6.4％は糖尿病予備軍、6.5％以上は糖尿病を示します。

さらに、世界中でのがん患者の増加も、臨床診断の需要を高めています。一般に、がんの早期診断は症状のある患者をできるだけ早期に発見することを重視することで、よりよい治療の可能性を高めます。例えば、GLOBOCAN Observatoryが2020年に発表したデータによると、同年には世界中で約1,930万件の新たながん症例が報告されています。

さらに、COVID-19のようなウイルス性疾患、細菌性疾患、真菌性疾患などの感染症の急増も、臨床診断の需要を世界的に高め、予測期間に市場を押し上げると見込まれます。例えば、世界保健機関（WHO）が2023年に発表した統計によると、結核は死因の第13位であり、COVID-19に次ぐ第2位の感染性の死因です。さらに、2020年に世界中で約1,000万人が結核に罹患すると報告されています。したがって、世界中での感染症の負担の増加が、今後数年間の臨床診断市場の成長を促進する可能性が高いです。

しかし、正確な診断検査や機器の開発における課題と、臨床診断検査機器にかかる高いコストが、市場成長の抑制要因となっています。

COVID-19パンデミックはその初期においてさまざまな医療部門に悪影響を及ぼしましたが、臨床診断市場は手つかずのままでした。これは、COVID-19の診断を増加させるための政府機関の連携や戦略的パートナーシップによるものです。例えば、2020年9月28日、世界保健機関（WHO）、アフリカ疾病管理予防センター（Africa CDC）、ビル&メリンダ・ゲイツ財団、Clinton Health Access Initiative（CHAI）、Foundation for Innovative New Diagnostics（FIND）、Global Fund、Unitaidは、低中所得国に高品質のCOVID-19抗原迅速検査を提供する契約を締結しました。

さらに、COVID-19の検出に用いるさまざまな診断キットが承認されたことも、パンデミック中の臨床診断市場を急成長させました。例えば、2022年3月17日、米国食品医薬品局（FDA）は、Biofire Diagnostics, LLCに対し、マルチターゲット検査において、SARS-CoV-2呼吸器感染症の原因となる微生物やその他の微生物から呼吸器検体中の核酸ターゲットを検出および同定する機器「BioFire Respiratory Panel 2.1（RP2.1）」の販売承認を与えました。このように、前述のすべての要因がパンデミック時の臨床診断市場の成長に寄与しました。

当レポートでは、世界の臨床診断市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 臨床診断市場レポートのイントロダクション

第2章 臨床診断市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制と特許の分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 臨床診断市場の主な要因の分析

  • 臨床診断市場の促進要因
    • さまざまな慢性疾患や感染症による負担の増大
    • ポイントオブケア臨床診断検査の採用の増加
    • 製品ポートフォリオにおける技術の進歩
    • 新製品の開発やラボにおける臨床診断の拡大に向けた、メーカーの戦略的事業活動の高まり
  • 臨床診断市場の抑制要因と課題
    • 臨床診断検査機器に関連する高いコスト
    • 正確な診断検査と機器の開発における課題
  • 臨床診断市場の機会
    • 低中所得国における臨床診断への容易なアクセスを提供する政府の取り組みの高まりが、市場に機会をもたらす可能性がある
    • 発展途上国における臨床診断ラボの設立の増加も、市場に機会をもたらす可能性がある

第5章 臨床診断のポーターのファイブフォース分析

第6章 臨床診断市場に対するCOVID-19の影響分析

第7章 臨床診断市場のレイアウト

  • タイプ別
    • 製品タイプ
    • サービス
  • 検査別
    • 全血球計算
    • 代謝パネル
    • 脂質パネル
    • がん検査パネル
    • 肝臓パネル
    • 感染症検査
    • その他
  • エンドユーザー別
    • 病院
    • 病理学研究所
    • 診療所
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 臨床診断の企業と製品のプロファイル

  • Abbott
  • BD
  • F. Hoffmann-La Roche Ltd
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Siemens AG
  • Hologic, Inc.
  • Qiagen NV
  • Quest Diagnostics Inc.
  • Thermo Fisher Scientific
  • Sysmex
  • Sonic Healthcare Ltd
  • Exact Sciences Corporation
  • NeoGenomics, Inc.
  • BioReference Laboratories
  • Laboratory Corporation of America® Holdings
  • DiaSorin
  • PerkinElmer Inc.
  • FUJIFILM Corporation

第9章 KOLの見解

第10章 プロジェクトのアプローチ

第11章 DelveInsightについて

第12章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis on Clinical Diagnostics Market
  • Table 3: Clinical Diagnostics Market Analysis in Global (2021-2030)
  • Table 4: Clinical Diagnostics Market Analysis in Global by Type (2021-2030)
  • Table 5: Clinical Diagnostics Market Analysis in Global by Test (2021-2030)
  • Table 6: Clinical Diagnostics Market Analysis in Global by End User (2021-2030)
  • Table 7: Clinical Diagnostics Market Analysis in Global by Geography (2021-2030)
  • Table 8: Clinical Diagnostics Market Analysis in North America (2021-2030)
  • Table 9: Clinical Diagnostics Market Analysis in North America by Country (2021-2030)
  • Table 10: Clinical Diagnostics Market Analysis in the US (2021-2030)
  • Table 11: Clinical Diagnostics Market Analysis in Canada (2021-2030)
  • Table 12: Clinical Diagnostics Market Analysis in Mexico (2021-2030)
  • Table 13: Clinical Diagnostics Market Analysis in Europe (2021-2030)
  • Table 14: Clinical Diagnostics Market Analysis in Europe by Country (2021-2030)
  • Table 15: Clinical Diagnostics Market Analysis in France (2021-2030)
  • Table 16: Clinical Diagnostics Market Analysis in Germany (2021-2030)
  • Table 17: Clinical Diagnostics Market Analysis in the UK (2021-2030)
  • Table 18: Clinical Diagnostics Market Analysis in Italy (2021-2030)
  • Table 19: Clinical Diagnostics Market Analysis in Spain (2021-2030)
  • Table 20: Clinical Diagnostics Market Analysis in Russia (2021-2030)
  • Table 21: Clinical Diagnostics Market Analysis in Rest of Europe (2021-2030)
  • Table 22: Clinical Diagnostics Market Analysis in Asia-Pacific (2021-2030)
  • Table 23: Clinical Diagnostics Market Analysis in Asia-Pacific by Country (2021-2030)
  • Table 24: Clinical Diagnostics Market Analysis in China (2021-2030)
  • Table 25: Clinical Diagnostics Market Analysis in Japan (2021-2030)
  • Table 26: Clinical Diagnostics Market Analysis in India (2021-2030)
  • Table 27: Clinical Diagnostics Market Analysis in Australia (2021-2030)
  • Table 28: Clinical Diagnostics Market Analysis in South Korea (2021-2030)
  • Table 29: Clinical Diagnostics Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Table 30: Clinical Diagnostics Market Analysis in Rest of World (2021-2030)
  • Table 31: Clinical Diagnostics Market Analysis in Rest of World by Region (2021-2030)
  • Table 32: Clinical Diagnostics Market Analysis in the Middle East (2021-2030)
  • Table 33: Clinical Diagnostics Market Analysis in Africa (2021-2030)
  • Table 34: Clinical Diagnostics Market Analysis in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis on Clinical Diagnostics Market
  • Figure 3: Clinical Diagnostics Market Analysis in Global (2021-2030)
  • Figure 4: Clinical Diagnostics Market Analysis in Global by Type (2021-2030)
  • Figure 5: Clinical Diagnostics Market Analysis in Global by Test (2021-2030)
  • Figure 6: Clinical Diagnostics Market Analysis in Global by End User (2021-2030)
  • Figure 7: Clinical Diagnostics Market Analysis in Global by Geography (2021-2030)
  • Figure 8: Clinical Diagnostics Market Analysis in North America (2021-2030)
  • Figure 9: Clinical Diagnostics Market Analysis in North America by Country (2021-2030)
  • Figure 10: Clinical Diagnostics Market Analysis in the US (2021-2030)
  • Figure 11: Clinical Diagnostics Market Analysis in Canada (2021-2030)
  • Figure 12: Clinical Diagnostics Market Analysis in Mexico (2021-2030)
  • Figure 13: Clinical Diagnostics Market Analysis in Europe (2021-2030)
  • Figure 14: Clinical Diagnostics Market Analysis in Europe by Country (2021-2030)
  • Figure 15: Clinical Diagnostics Market Analysis in France (2021-2030)
  • Figure 16: Clinical Diagnostics Market Analysis in Germany (2021-2030)
  • Figure 17: Clinical Diagnostics Market Analysis in the UK (2021-2030)
  • Figure 18: Clinical Diagnostics Market Analysis in Italy (2021-2030)
  • Figure 19: Clinical Diagnostics Market Analysis in Spain (2021-2030)
  • Figure 20: Clinical Diagnostics Market Analysis in Russia (2021-2030)
  • Figure 21: Clinical Diagnostics Market Analysis in Rest of Europe (2021-2030)
  • Figure 22: Clinical Diagnostics Market Analysis in Asia-Pacific (2021-2030)
  • Figure 23: Clinical Diagnostics Market Analysis in Asia-Pacific by Country (2021-2030)
  • Figure 24: Clinical Diagnostics Market Analysis in China (2021-2030)
  • Figure 25: Clinical Diagnostics Market Analysis in Japan (2021-2030)
  • Figure 26: Clinical Diagnostics Market Analysis in India (2021-2030)
  • Figure 27: Clinical Diagnostics Market Analysis in Australia (2021-2030)
  • Figure 28: Clinical Diagnostics Market Analysis in South Korea (2021-2030)
  • Figure 29: Clinical Diagnostics Market Analysis in Rest of Asia-Pacific (2021-2030)
  • Figure 30: Clinical Diagnostics Market Analysis in Rest of World (2021-2030)
  • Figure 31: Clinical Diagnostics Market Analysis in Rest of World by Country (2021-2030)
  • Figure 32: Clinical Diagnostics Market Analysis in the Middle East (2021-2030)
  • Figure 33: Clinical Diagnostics Market Analysis in Africa (2021-2030)
  • Figure 34: Clinical Diagnostics Market Analysis in South America (2021-2030)
  • Figure 35: Market Drivers
  • Figure 36: Market Barriers
  • Figure 37: Market Opportunities
  • Figure 38: PORTER's Five Force Analysis
目次
Product Code: DIMDCL0528

Clinical Diagnostics Market By Type (Product Type [Instruments, Kits & Reagents], Services), By Test (Complete Blood Count, Metabolic Panel, Lipid Panel, Cancer Testing Panel, Liver Panel, Infectious Disease Testing, Others), By End-User (Hospitals, Pathology Labs, Clinics, And Others), by geography, is expected to expand at a significant CAGR till 2030 owing to the growing cases of various chronic diseases & infectious diseases across the globe and rise in integration of technological advancements in the product portfolio

The global clinical diagnostics market was valued at USD 70.11 billion in 2023, growing at a CAGR of 7.02% during the forecast period from 2024 to 2030. The escalating demand for clinical diagnostics is primarily attributed to the rising burden of various chronic disorders such as liver disorder, blood disorder, and cancer among others. In addition, an increase in the adoption of point of care clinical diagnostic tests, rising strategic business activities for establishing new clinical diagnostic labs, worldwide, and growing technological advancement in the product portfolio, among others are expected to bolster the global clinical diagnostic market during the forecast period from 2024-2030.

Clinical Diagnostics Market Dynamics:

The market for clinical diagnostics is gaining momentum at present owing to the surge in the cases of various chronic disorder such as cardiovascular disorder, diabetes, cancer, and others.

According to the International Diabetes Federation's statistics published in the year 2023, an estimated 537 million adults (20-79 years) were living with diabetes in the same year. Moreover, the stats also projected the diabetes cases to rise to 643 million by 2030 and 783 million by 2045.

Clinical diagnostic tests have a decisive impact in the early diagnosis of all kinds of diseases and further help in their proper management. For instance, the A1C test measures the average blood sugar level over the past 2 or 3 months. The test value below 5.7% is normal, between 5.7 and 6.4% indicates prediabetes, and 6.5% or higher indicates diabetes.

Furthermore, the rising cases of cancer across the globe are also likely to increase the demand for clinical diagnosis. Early diagnosis of cancer generally increases the chances of an improved treatment by focusing on detecting symptomatic patients as early as possible. For instance, according to the data published by the GLOBOCAN Observatory in the year 2020, approximately 19.3 million new cancer cases were reported across the globe in the same year.

Additionally, the spike in infectious diseases such as viral diseases such as COVID-19, bacterial diseases, fungal diseases, among others is also expected to raise the demand for clinical diagnosis, worldwide thereby increasing the market during the forecasted period. For instance, according to the statistic revealed by the World Health Organization (WHO) in the year 2023, tuberculosis (TB) is the 13th leading cause of death and the second-leading infectious killer after COVID-19. Moreover, the data also reported that in the year 2020, about 10 million people fell ill with tuberculosis (TB) worldwide. Hence, the growing burden of infectious diseases across the globe is likely to drive the growth of the clinical diagnostics market in the upcoming years.

However, the challenges in the development of accurate diagnostic tests and equipment and the high cost associated with clinical diagnostic lab equipment are some of the factors likely to sluggish the market growth.

Although the COVID-19 pandemic had an adverse impact on various healthcare sectors during the initial phases but the market for clinical diagnostics remained untouched. This is owing to the collaborations and strategic partnerships among the governmental organizations to increase the diagnosis of COVID-19 infection. For instance, on September 28, 2020, the World Health Organization (WHO), the Africa Centres for Disease Control and Prevention (Africa CDC), the Bill & Melinda Gates Foundation, the Clinton Health Access Initiative (CHAI), the Foundation for Innovative New Diagnostics (FIND), the Global Fund, Unitaid entered into an agreement to make available high quality COVID-19 antigen rapid tests to low and middle-income countries.

Moreover, approval of various diagnostic kits for the detection of COVID-19 infection also surged the market for clinical diagnostics during the pandemic. For instance, on March 17, 2022, the US Food and Drug Administration (FDA) granted marketing authorization to Biofire Diagnostics, LLC for "BioFire Respiratory Panel 2.1 (RP2.1)" a device to detect and identify nucleic acid targets in respiratory specimens from microbial agents that cause the SARS-CoV-2 respiratory infection and other microbial agents when in a multi-target test. Thus, all the aforementioned factors contributed to the growth of the clinical diagnostic market during the pandemic.

Clinical Diagnostics Market Segment Analysis:

Clinical Diagnostics Market By Type (Product Type [Instruments, Kits & Reagents], Services), By Test (Complete Blood Count, Metabolic Panel, Lipid Panel, Cancer Testing Panel, Liver Panel, Infectious Disease Testing, Others), By End-User (Hospitals, Pathology Labs, Clinics, And Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the test segment of Clinical Diagnostics market, the cancer testing panel is expected to hold a significant market share in the year 2023. The rising incidence of various cancers such as prostate cancer, lung cancer, and stomach cancer among others is likely to increase the demand for various tests available in the cancer testing panel, thus increasing the overall segment market. For instance, as per the WHO 2022 report, there were an estimated 2.21 million lung cancer cases were diagnosed in the year 2020. Moreover, as per the same data source, lung cancer affected approximately 2.21 million cases, globally in the year 2020.

In addition, various cancer tests obtaining reimbursement or insurance coverage could also be a potential factor driving the market for cancer testing panels. For instance, on January 01, 2020, ipsogen JAK2 DX reagent (a gene testing kit that measures the JAK2V617F mutation1 quantitatively, was used in the diagnosis of certain hematopoietic tumors generally referred to as blood cancers, specifically polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)) developed by Sysmex Corporation obtained health insurance coverage and became Japan's first diagnostic aid for PV, ET, and PMF to be covered.

Moreover, companies collaborating to develop new blood-based cancer detection test would also increase the adoption of cancer detection tests among the population as they are non-invasive tests for detecting cancer, thereby augmenting the segmental market growth. For instance, in May 2022, Singaporean molecular diagnostic company Tzar Labs in collaboration with India-based Epigeneres Biotechnology has developed a new blood-based test to identify and categorize solid tumors, hematological malignancies, and sarcomas according to their stage.

Thus, all the above-mentioned factors are likely to upsurge the market for cancer detection panels in clinical diagnostics.

North America is expected to dominate the overall Clinical Diagnostics Market:

Among all the regions, North America is expected to hold a major share in the overall clinical diagnostics market in the year 2023. This domination is owing to the growing prevalence of various ailments such as infectious diseases, chronic disorders, deficiency disorders, and others in the region. In addition, rising product approvals, growing focus on R&D activities by the key manufacturers for developing and launching various clinical diagnosis products, and rising government initiatives in the region for promoting wider adoption of point-of-care clinical diagnosis methods, among others are the factors responsible for the growth of North America clinical diagnostic market.

For instance, as per the data published by the Centers for Disease Control and Prevention (CDC) in the year 2020, approximately 24.6% (61 million) of adults had 1 chronic condition, and 27.2% (68 million) had >=2 chronic conditions in America in the year 2018.

Also, increasing lifestyle-associated disorders such as obesity, hypertension, among others could increase the market for clinical diagnoses in the country. According to the CDC 2020 report, the age-adjusted prevalence of obesity among U.S. adults was 42.4% from 2017 to 2018.

Furthermore, companies scaling up laboratory testing by launching new products would also increase the clinical diagnostic market in the country.

For instance, on May 04, 2022, Beckman Coulter, a clinical diagnostics leader, launched the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.

Moreover, as per the US Department of Health and Human Services (HHS) press release in the year 2023, the US government had invested USD 650 million in rapid diagnostic testing in the latest action to increase access to tests.

Thus, all the above-mentioned factors are likely to increase the market for clinical diagnostics in the region during the forthcoming years.

Clinical Diagnostics Market Key Players:

Some of the key market players operating in the Clinical Diagnostics market include Abbott, BD, bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, Siemens AG, Hologic, Inc., Qiagen NV, Quest Diagnostics Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Sysmex, Sonic Healthcare Ltd, Exact Sciences Corporation, NeoGenomics, Inc., BioReference Laboratories, Laboratory Corporation of America® Holdings, DiaSorin, PerkinElmer Inc., FUJIFILM Corporation, and others.

Recent Developmental Activities in the Clinical Diagnostics Market:

On July 26, 2022, Beckman Coulter, a global clinical diagnostics leader, entered into definitive agreements with Quidel Corporation to obtain all rights related to the manufacture, distribution, and sale of a BNP assay for Beckman Coulter analyzers. Under the terms of the agreements, Quidel will continue to manufacture and supply certain components to Beckman Coulter related to the assay, and Beckman Coulter will exclusively manufacture and sell to customers the BNP assay currently sold as TRIAGE® BNP by Quidel, under the brand name Access BNP.

On April 13, 2022, Ortho Clinical Diagnostics, one of the world's largest in-vitro diagnostics companies received CE Marking for its VITROS® SARS-CoV-2 Antigen Test.

On November 19, 2020, Bio-Rad was granted authorization to sell or import the Platelia SARS-CoV-2 Total Ab test for COVID-19 testing in Canada.

Key Takeaways from the Clinical Diagnostics Market Report Study

  • Market size analysis for current market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Clinical Diagnostics market.
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened in the last 3 years
  • Key companies dominating the Global Clinical Diagnostics Market.
  • Various opportunities available for the other competitor in the Clinical Diagnostics Market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Clinical Diagnostics market growth in the coming future?

Target Audience who can be benefited from the Clinical Diagnostics Market Report Study

  • Clinical Diagnostics providers
  • Research organizations and consulting companies
  • Clinical Diagnostics-related organization, association, forum, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders in Clinical Diagnostics
  • Various End-users want to know more about the Clinical Diagnostics Market and the latest technological developments in the Clinical Diagnostics market.

Frequently Asked Questions for the Clinical Diagnostics Market:

1. What is Clinical Diagnostics?

Clinical diagnostic is a process of identifying a disease or a condition based on the signs and symptoms of a patient by physical examination or lab test. Clinical diagnostics may include a variety of tests such as lipid panel tests, blood tests, cancer tests, among others

2. What is the market for Global Clinical Diagnostics?

The global Clinical Diagnostics Market was valued at USD 70.11 billion in 2023, growing at a CAGR of 7.02% during the forecast period from 2024 to 2030.

3. What are the drivers for Global Clinical Diagnostics?

The major factors driving the demand for Clinical Diagnostics are the rising burden of various chronic disorders such as liver disorders, blood disorders, and cancer among others. In addition, an increase in the adoption of point of care clinical diagnostic tests, rising strategic business activities for establishing new clinical diagnostic labs, worldwide, and growing technological advancement in the product portfolio, among others are expected to bolster the global clinical diagnostic market during the forecast period from 2024-2030.

4. Who are the key players operating in Global Clinical Diagnostics?

Some of the key market players operating in the Clinical Diagnostics market include Abbott, BD, bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation, Siemens AG, Hologic, Inc., Qiagen NV, Quest Diagnostics Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Sysmex, Sonic Healthcare Ltd, Exact Sciences Corporation, NeoGenomics, Inc., BioReference Laboratories, Laboratory Corporation of America® Holdings, DiaSorin, PerkinElmer Inc., FUJIFILM Corporation, and others.

5. Which region has the highest share in the Clinical Diagnostics market?

Among all the regions, North America is expected to hold a major share in the overall clinical diagnostics market during the forecasted period. This domination is owing to the growing prevalence of various ailments such as infectious diseases, chronic disorders, deficiency disorders, and others in the region. In addition, rising product approvals, growing focus on R&D activities by the key manufacturers for developing and launching various clinical diagnosis products, and rising government initiatives in the region for promoting wider adoption of point-of-care clinical diagnosis methods, among others are the factors responsible for the growth of clinical diagnostic market.

Table of Contents

1.Clinical Diagnostics Market Report Introduction

2.Clinical Diagnostics Market Executive summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory and Patent Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Clinical Diagnostics Market Key factors analysis

  • 4.1. Clinical Diagnostics Market Drivers
    • 4.1.1. The rising burden of various chronic disorders and Infectious diseases
    • 4.1.2. The increase in the adoption of point of care clinical diagnostic tests
    • 4.1.3. Growing technical advancement in the product portfolio
    • 4.1.4. Rising strategic business activities among the manufacturers for developing new products and scaling up clinical diagnosis in labs
  • 4.2. Clinical Diagnostics Market Restraints and Challenges
    • 4.2.1. High cost associated with clinical diagnostic lab equipment
    • 4.2.2. Challenges in the development of accurate diagnostic tests and equipment
  • 4.3. Clinical Diagnostics Market Opportunities
    • 4.3.1. The rise in government initiatives to provide easy access to clinical diagnosis in low and middle-income nations may provide an opportunity for the market
    • 4.3.2. An increase in the setting up of clinical diagnostic labs in developing nations could also provide an opportunity for the market

5. Clinical Diagnostics Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Clinical Diagnostics Market

7. Clinical Diagnostics Market layout

  • 7.1. By Type
    • 7.1.1. Product Type
      • 7.1.1.1. Instruments
      • 7.1.1.2. Kits & Reagents
    • 7.1.2. Services
  • 7.2. By Test
    • 7.2.1. Complete Blood Count
    • 7.2.2. Metabolic Panel
    • 7.2.3. Lipid Panel
    • 7.2.4. Cancer Testing Panel
    • 7.2.5. Liver panel
    • 7.2.6. Infectious Disease Testing
    • 7.2.7. Others
  • 7.3. By End-user
    • 7.3.1. Hospitals
    • 7.3.2. Pathology labs
    • 7.3.3. Clinics
    • 7.3.4. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States
      • 7.4.1.2. Canada
      • 7.4.1.3. Mexico
    • 7.4.2. Europe
      • 7.4.2.1. France
      • 7.4.2.2. Germany
      • 7.4.2.3. United Kingdom
      • 7.4.2.4. Italy
      • 7.4.2.5. Spain
      • 7.4.2.6. Russia
      • 7.4.2.7. Rest of Europe
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China
      • 7.4.3.2. Japan
      • 7.4.3.3. India
      • 7.4.3.4. Australia
      • 7.4.3.5. South Korea
      • 7.4.3.6. Rest of Asia Pacific
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East
      • 7.4.4.2. Africa
      • 7.4.4.3. South America

8. Clinical Diagnostics Company and Product Profiles

  • 8.1. Abbott
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. BD
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. F. Hoffmann-La Roche Ltd
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. bioMerieux SA
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Bio-Rad Laboratories, Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Danaher Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Siemens AG
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Hologic, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Qiagen NV
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Quest Diagnostics Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Thermo Fisher Scientific
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Sysmex
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Sonic Healthcare Ltd
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Exact Sciences Corporation
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. NeoGenomics, Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. BioReference Laboratories
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Laboratory Corporation of America® Holdings
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. DiaSorin
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. PerkinElmer Inc.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. FUJIFILM Corporation
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us